Evidence map›Paper›PMID 30170631›Full record

ArticleActa neuropathologica communications2018

Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors.

Leomar Y Ballester, Guangrong Lu, Soheil Zorofchian, Venkatrao Vantaku, Vasanta Putluri, Yuanqing Yan, Octavio Arevalo, Ping Zhu, Roy F Riascos, Arun Sreekumar and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Leomar Y BallesterDepartment of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, 6431 Fannin St., MSB 2.136, Houston, TX, 77030, USA. leomar.y.ballester@uth.tmc.edu.ORCID 0000-0002-6854-6830
Guangrong LuDepartment of Neurosurgery, University of Texas Health Science Center at Houston, 6431 Fannin St., MSB 2.136, Houston, TX, 77030, USA.
Soheil ZorofchianDepartment of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, 6431 Fannin St., MSB 2.136, Houston, TX, 77030, USA.
Venkatrao VantakuDepartment of Molecular and Cellular Biology, Baylor College of Medicine, 120D, Jewish Building, One Baylor Plaza, Houston, TX, 77030, USA.
Vasanta PutluriAdvanced Technology Core, Baylor College of Medicine, Houston, TX, 77030, USA.
Yuanqing YanDepartment of Neurosurgery, University of Texas Health Science Center at Houston, 6431 Fannin St., MSB 2.136, Houston, TX, 77030, USA.
Octavio ArevaloDepartment of Radiology, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Ping ZhuDepartment of Neurosurgery, University of Texas Health Science Center at Houston, 6431 Fannin St., MSB 2.136, Houston, TX, 77030, USA.
Roy F RiascosDepartment of Radiology, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Arun SreekumarDepartment of Molecular and Cellular Biology, Baylor College of Medicine, 120D, Jewish Building, One Baylor Plaza, Houston, TX, 77030, USA.
Yoshua EsquenaziDepartment of Neurosurgery, University of Texas Health Science Center at Houston, 6431 Fannin St., MSB 2.136, Houston, TX, 77030, USA.
Nagireddy PutluriDepartment of Molecular and Cellular Biology, Baylor College of Medicine, 120D, Jewish Building, One Baylor Plaza, Houston, TX, 77030, USA. putluri@bcm.edu.
Jay-Jiguang ZhuDepartment of Neurosurgery, University of Texas Health Science Center at Houston, 6431 Fannin St., MSB 2.136, Houston, TX, 77030, USA.
The University of Texas Health Science Center at Houston · USBaylor College of Medicine · USMemorial Hermann · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9M
METABOLOMIC PROFILING AND BIOLOGIC BASIS OF RACIAL DISPARITY IN PROSTATE CANCERU01CA167234 · NCI · BAYLOR COLLEGE OF MEDICINE · PI PALAPATTU, GANESH S, SREEKUMAR, ARUN · 2012 to 2016
$1.9M
Racial Disparity in Bladder Cancer and Identification of Altered Metabolism in African American Compare to European Bladder CancerR01CA220297 · NCI · BAYLOR COLLEGE OF MEDICINE · PI PUTLURI, NAGIREDDY · 2017 to 2021
$1.8M
Delineating racially distinct metabolic pathways in triple negative breast cancerU01CA179674 · NCI · BAYLOR COLLEGE OF MEDICINE · PI SREEKUMAR, ARUN · 2014 to 2018
$1.7M
NCI NIH HHS P30 CA125123NCI NIH HHS R01 CA220297NCI NIH HHS U01 CA167234NCI NIH HHS U01 CA179674
6 · The paper itself

Abstract

Cancer cells have altered cellular metabolism. Mutations in genes associated with key metabolic pathways (e.g., isocitrate dehydrogenase 1 and 2, IDH1/IDH2) are important drivers of cancer, including central nervous system (CNS) tumors. Therefore, we hypothesized that the abnormal metabolic state of CNS cancer cells leads to abnormal levels of metabolites in the CSF, and different CNS cancer types are associated with specific changes in the levels of CSF metabolites. To test this hypothesis, we used mass spectrometry to analyze 129 distinct metabolites in CSF samples from patients without a history of cancer (n = 8) and with a variety of CNS tumor types (n = 23) (i.e., glioma IDH-mutant, glioma-IDH wildtype, metastatic lung cancer and metastatic breast cancer). Unsupervised hierarchical clustering analysis shows tumor-specific metabolic signatures that facilitate differentiation of tumor type from CSF analysis. We identified differences in the abundance of 43 metabolites between CSF from control patients and the CSF of patients with primary or metastatic CNS tumors. Pathway analysis revealed alterations in various metabolic pathways (e.g., glycine, choline and methionine degradation, dipthamide biosynthesis and glycolysis pathways, among others) between IDH-mutant and IDH-wildtype gliomas. Moreover, patients with IDH-mutant gliomas demonstrated higher levels of D-2-hydroxyglutarate in the CSF, in comparison to patients with other tumor types, or controls. This study demonstrates that analysis of CSF metabolites can be a clinically useful tool for diagnosing and monitoring patients with primary or metastatic CNS tumors.

Indexed as

AdultAgedBiomarkers, TumorBreast NeoplasmsCentral Nervous System NeoplasmsFemaleGliomaHumansImaging, Three-DimensionalIsocitrate DehydrogenaseLung NeoplasmsMagnetic Resonance ImagingMetabolomicsMiddle AgedMutationROC CurveBiomarkers, TumorIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseBrain tumorCSFGliomaHydroxyglutarateLiquid biopsyMetabolites

Identifiers

PMID30170631
PMCPMC6117959
OpenAlexW2889156144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.